Latest Lupin Pharmaceuticals Inc. Stories
MUMBAI, India and BALTIMORE, April 12, 2013 /PRNewswire/ -- Pharma major, Lupin Ltd., announced today that its subsidiary Lupin Pharmaceuticals Inc. (collectively Lupin) has received final approval for its Daysee(TM) Tablets (Levonorgestrel and Ethinyl Estradiol Tablets, USP, 0.15 mg/0.03 mg and Ethinyl Estradiol Tablets, USP, 0.01 mg) from the United States Food and Drugs Administration (US FDA) to market a generic version of Teva Branded Pharm.'s Seasonique Tablets(R). Lupin...
MUMBAI, India and BALTIMORE, February 22, 2013 /PRNewswire/ -- Approval to add to growing SUPRAX(R) Franchise Pharma major, Lupin Ltd., announced today that its subsidiary, Lupin Pharmaceuticals Inc. (collectively, Lupin) has received approval for SUPRAX(R) (Cefixime) for Oral Suspension, 500 mg/5mL from the United States Food and Drugs Administration (FDA). Lupin expects to commence shipping the product in the near future. The approval will expand Lupin's range...
MUMBAI and BALTIMORE, January 22, 2013 /PRNewswire/ -- Pharma major, Lupin Ltd., announced today that its subsidiary Lupin Pharmaceuticals Inc. (collectively Lupin) has received final approval for its Levonorgestrel and Ethinyl Estradiol Tablets USP, 0.1 mg / 0.02 mg from the United States Food and Drugs Administration (US FDA) to market a generic version of Watson Laboratories, Inc.'s Lutera(R) 28 Tablets. Lupin's Levonorgestrel and Ethinyl Estradiol Tablets are a...
BALTIMORE, Md., Nov. 15, 2012 /PRNewswire/ -- Vinita Gupta, CEO of Lupin Pharmaceuticals, Inc., was named the inaugural Ernst & Young U.S. 2012 Family Business Award of Excellence winner today at Ernst & Young LLP's 2012 Strategic Growth Forum in Palm Springs, CA. Gupta was born into the pharmaceutical business, but it was her guidance and vision that established Lupin Pharmaceuticals, Inc. ("LPI") as the U.S. wholly owned subsidiary of Lupin Ltd., the company founded...
MUMBAI, India and BALTIMORE, Maryland, October 18, 2012 /PRNewswire/ -- BSE: 500257 NSE: LUPIN REUTERS: LUPIN.BO BLOOMBERG: LPC IN Pharma major, Lupin Ltd., announced today that its subsidiary Lupin Pharmaceuticals Inc. (collectively Lupin) has received final approval for its oral contraceptive Kurvelo(R) Tablets (Levonorgestrel and Ethinyl Estradiol Tablets, USP) 0.15 mg/0.03 mg from the United States Food and Drugs Administration (FDA) to market a...
MUMBAI, India and BALTIMORE, Maryland, September 13, 2012 /PRNewswire/ -- Pharma major, Lupin Ltd., announced today that its subsidiary Lupin Pharmaceuticals Inc. (collectively, Lupin) has received final approval for its Escitalopram Tablets (Escitalopram oxalate) 5 mg, 10 mg, and 20 mg, from the United States Food and Drugs Administration (FDA) to market a generic version of Forest Laboratories, Inc.'s (Forest) Lexapro Tablets, 5 mg, 10 mg, and 20 mg. Lupin's...
BALTIMORE, July 6, 2012 /PRNewswire/ -- Ernst & Young LLP today announced that Ms. Vinita Gupta, CEO of Lupin Pharmaceuticals, Inc., received the Ernst & Young Entrepreneur Of The Year® 2012 Award in the Health Services and Technology category in Maryland. The award recognizes outstanding entrepreneurs who demonstrate excellence and extraordinary success in such areas as innovation, financial performance and personal commitment to their businesses and communities. Vinita...
MUMBAI and BALTIMORE, July 5, 2012 /PRNewswire/ -- Pharma major, Lupin Ltd., announced today that its subsidiary, Lupin Pharmaceuticals Inc. (collectively, Lupin) has received final approval for its Pregabalin Capsules, 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg and 300 mg from the United States Food and Drugs Administration (FDA) to market a generic version of C.P. Pharmaceuticals C.V., LYRICA(R) (Pregabalin) capsules. Lupin's Pregabalin Capsules, 25 mg, 50...
MUMBAI and BALTIMORE, July 3, 2012 /PRNewswire/ -- BSE : 500257 NSE: Lupin REUTERS: LUPN.BO BLOOMBERG: LPC IN Pharma major, Lupin Ltd., announced today that its subsidiary, Lupin Pharmaceuticals Inc. (collectively, Lupin) has received approval for its Norgestimate and Ethinyl Estradiol Tablets, 0.18 mg/0.025 mg, 0.215 mg/0.025 mg, and 0.25 mg/0.025 mg from the United States Food and Drugs Administration (FDA). Lupin's...
MUMBAI, India and BALTIMORE, June 5, 2012 /PRNewswire/ -- Pharma major, Lupin Ltd., announced today that its subsidiary, Lupin Pharmaceuticals Inc. (collectively, Lupin) has received approval for SUPRAX(R) (Cefixime) Capsules 400 mg from the United States Food and Drugs Administration (FDA). Lupin expects to commence shipping the product in the near future. The approval will expand Lupin's range of SUPRAX(R) dosage forms available to treat the approved indications in...
